Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib
This article was originally published in Scrip
Galapagos NV, which suffered a major shock in September when AbbVie decided not to exercise its option on their JAK1 inhibitor filgotinib, has secured $725m up front from Gilead Sciences Inc. for the promising rheumatoid arthritis treatment.
You may also be interested in...
Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib
On pace to file selective JAK1 inhibitor filgotinib for US approval in RA by year’s end, Gilead says the drug’s safety profile may allow for a labeling advantage compared with other drugs in the class.
AbbVie To Take Flight From Galapagos As PELICAN Flounders?
Lacklustre top-line data from the PELICAN study raise concerns over AbbVie's commitment to Galapagos's cystic fibrosis franchise, and leaves rival Vertex even more securely in possession of the field.
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Gilead reported an expected and continued sales decline in HCV – an area in which the company soon will be done with R&D, since unmet needs have been filled or will be soon by drug regimens from Gilead and its competitors. The company is hunting new assets, but taking a disciplined approach on price and quality.